Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H1 2018

  • ID: 4464906
  • Drug Pipelines
  • 42 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aviragen Therapeutics Inc
  • Ennaid Therapeutics LLC
  • Toray Industries Inc
  • MORE
Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H1 2018

Summary:

Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 13 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H1 2018, outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hepatitis C Virus Envelope Protein E2 - E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens. The molecules developed by companies in Phase II and Preclinical stages are 1 and 5 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 3 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C and Genital Warts (Condylomata Acuminata).

Furthermore, this report also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2
  • The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aviragen Therapeutics Inc
  • Ennaid Therapeutics LLC
  • Toray Industries Inc
  • MORE
Introduction

The Publisher's Report Coverage

Hepatitis C Virus Envelope Protein E2 - Overview

Hepatitis C Virus Envelope Protein E2 - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development

Aviragen Therapeutics Inc

Ennaid Therapeutics LLC

Integrated BioTherapeutics Inc

Toray Industries Inc

Hepatitis C Virus Envelope Protein E2 - Drug Profiles

CIGB-230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C (strain H77) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C (virus-like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hepatitis C vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit E2 for Hepatitis C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit E1 and E2 Glycoprotein for HCV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teslexivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatitis C Virus Envelope Protein E2 - Dormant Products

Hepatitis C Virus Envelope Protein E2 - Discontinued Products

Hepatitis C Virus Envelope Protein E2 - Product Development Milestones

Featured News & Press Releases

Nov 29, 2017: Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma

Feb 08, 2016: Biota Commences Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma

Oct 31, 2013: Results of Anaconda Pharma's Phase IIa study released

Jun 10, 2013: IBT and Stanford Awarded STTR

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Aviragen Therapeutics Inc, H1 2018

Pipeline by Ennaid Therapeutics LLC, H1 2018

Pipeline by Integrated BioTherapeutics Inc, H1 2018

Pipeline by Toray Industries Inc, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aviragen Therapeutics Inc
  • Ennaid Therapeutics LLC
  • Integrated BioTherapeutics Inc
  • Toray Industries Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll